Biologic Therapy

Siliq demonstrated skin clearance and improved quality of life in adult patients with moderate to severe plaque psoriasis with no new safety signals emerging throughout 5 years of treatment in a phase 2, open-label extension study.

Researchers compiled a treatment algorithm for cutaneous manifestations of lupus erythematosus based on data from 104 studies, according to a study presented at the American College of Rheumatology/Association of Rheumatology Professionals annual meeting.

Direct-to-consumer advertisements in health care occasionally provide patients with helpful information that sends them into the clinic with appropriate questions for their doctor. These questions, then, occasionally spark frank conversations that occasionally translate into shared decision-making to produce positive outcomes.

The new guidelines from the American Academy of Dermatology and the National Psoriasis Foundation are the first of its kind to focus on pediatric psoriasis, according to Joel M. Gelfand, MD, MSCE, professor of dermatology and epidemiology at University of Pennsylvania Perelman School of Medicine.

UCB announced positive results from BE READY, the second of three phase 3 studies to report on bimekizumab this year.

I am feeling rather nostalgic at the moment. Perhaps it’s just because summer is drawing to a close and autumn is on its way. No? Perhaps it’s because this is a banner year of nostalgia as one of my favorite books, The House of God by Samuel Shem — which I have read three times — is now celebrating its 40th anniversary. No! Please, this isn’t true.

Patients with psoriasis prescribed biologic agents are less likely to develop psychiatric illnesses compared with patients not prescribed biologic agents, which researchers concluded is due to treatment selection bias.

In patients with psoriasis, the median time between first and last biologic prescriptions was between 3.3 and 7 months with up to 50% of patients not prescribed a second prescription for the medication, according to researchers in Journal of Drugs in Dermatology.

Adults with active ankylosing spondylitis despite treatment with a first TNF-inhibitor, as well as those with stable disease receiving an originator TNF inhibitor, should not be switched to a biosimilar, according to updated recommendations from the American College of Rheumatology published in Arthritis Care & Research.

August is Psoriasis Action Month, a national initiative to encourage understanding and enhance education about this common disease. According to the National Psoriasis Foundation, psoriasis affects more than 8 million Americans and roughly 125 million people worldwide.